|Cat. No. HS-439 017||
100 µg purified IgG, lyophilized. Albumin and azide were added for stabilization. For reconstitution add 100 µl H2O to get a 1mg/ml solution in PBS. Then aliquot and store at -20°C to -80°C until use.
Antibodies should be stored at +4°C when still lyophilized. Do not freeze!
Immunocytochemistry (ICC) on 4% PFA fixed cells. Immunoreactivity is usually revealed by fluorescence. Some antibodies require special fixation methods. For details, please refer to the “Remarks” section.', $event)" style="cursor: help;">ICC: gallery
Immunohistochemistry (IHC) on 4% PFA perfusion fixed tissue with 24h PFA post fixation. Immunoreactivity is usually revealed by fluorescence or a chromogenic substrate. Some antibodies require special fixation methods or antigen retrieval steps. For details, please refer to the ”Remarks” section.', $event)" style="cursor: help;">IHC: 1 : 200 gallery
Immunohistochemistry (IHC-P) of formalin fixed, paraffin embedded (FFPE) tissue (some antibodies require special antigen retrieval steps, please refer to the ”Remarks” section). Immunoreactivity is usually revealed by fluorescence or a chromogenic substrate.', $event)" style="cursor: help;">IHC-P: 1 : 100 gallery
Immunohistochemistry on fresh frozen (IHC-Fr) cryo-tissue-sections. In contrast to standard PFA perfusion fixed tissues, fresh frozen cryo-tissue-sections can be variably postfixed with alcohols, acetone or PFA. Alcohol or acetone fixation is e.g. of advantage for antigens masked by PFA crosslinking. For recommended postfixation, please refer to the ”Remarks” section. Immunoreactivity is usually revealed by fluorescence or a chromogenic substrate.', $event)" style="cursor: help;">IHC-Fr: 1 : 200 (see remarks) gallery
|Subtype||IgG2b (κ light chain)|
|Immunogen||Synthetic peptide corresponding to AA 527 to 547 from mouse CD19 (UniProt Id: P25918)|
Reacts with: mouse (P25918).
No signal: human (P15391), rat.
Other species not tested yet.
IHC-Fr: PFA and MeOH fixation are recommended.
Chromogenic double staining for CD19 (DAB) and CD3e (RED) visualized T-cell and B-cell populations in the mouse spleen
CD19 (Cluster of Differentiation 19) is a B cell-restricted signal-transduction molecule that plays an important role in the regulation of development, activation, and differentiation of B-lymphocytes. CD19 is considered as a biomarker for B-cells because of its continued expression from very early B cell development stages, being evident already on pro-B cells and on all later B cell stages, until plasma cell terminal differentiation, when its expression is lost. In complex with CD21 (complement receptor-2), CD81 and CD225 (Leu-13), CD19 functions as a dominant signaling receptor on the surface of mature B cells (1). CD19 is instrumental in B cell homeostasis and lowers the threshold of B cell receptor crosslinking necessary to effect B-cell activation and sustain proliferation upon antigen encounter (2). Dysregulated CD19 expression has been implicated in several autoimmune diseases and CD19 is expressed in most acute lymphoblastic leukemias (ALL), chronic lymphocytic leukemias (CLL) and other B cell lymphomas (3). Therefore, CD19 has gained attention as a potential target in the therapy of B-cell malignancies (4).